FAP and neoplasm: Similarly, FAPI-04 conjugated with albumin binder (4-[p-iodophenyl] butyric acid moiety, truncated Evans blue moiety, lauric acid [C12], and palmitic acid [C16]) was developed (TEFAPI-06, TEFAPI-07, FAPI-C12, and FAPI-C16) to improve tumor retention (Figure 5B), and novel FAPI-variants showed notable tumor growth inhibition after radiolabeling with 177Lu in pancreatic cancer patient-derived xenografts (PDXs) and HT-1080-FAP xenografts 71, 72.